Recurrent Cytomegalovirus (CMV) Infection in Solid Organ Transplant (SOT) Patients: Incidence, Risk Factors and Outcomes (ATC 2026) - Jun 17, 2026 - Abstract #Abstract B382; Pres time: Jun 21, 2026; 02:45 PM - 03:45 PM; Location: Exhibit Hall; "Recurrence of CMV is common in SOT recipients, but the majority were not clinically significant and did not require antiviral treatment. Higher viral load and faster time to peak viral load at index CMV episode were significant risk factors for CMV recurrence.Baseline and Index CMV Infection Characteristics as well as 1-Year Outcomes by Recurrence StatusCharacteristicNo Recurrence (n=33)Recurrence (n=32)Total (N=65)P ValueAge at index CMV (Cytomegalovirus), in years56 (45 - 62)61 (48.75 - 64)58 (48 - 64)0.382Induction immunosuppression:0.606Lymphocyte-nondepleting (Basiliximab, Steroids only)56 (45 - 62)22 (68.8%)42 (64.6%)Lymphocyte-depleting (Thymoglobulin, Alemtuzumab)13 (39.4%)10 (31.2%)23 (35.4%)Maintenance immunosuppression at index CMV, n (%)1.000Triple regimen (Calcineurin inhibitor + antimetabolite + steroid)26 (78.8%)26 (81.2%)52 (80%)Dual/Mono regimen (Any 1 or 2 of the agents above)7 (21.2%)6 (18.8%)13 (20%)Index initial VL (Viral load) (log10 IU/mL),..."
Clinical • Cytomegalovirus Infection • Infectious Disease • Solid Organ Transplantation • Transplant Rejection • Transplantation
|
|
A. N. Mughrabi; M. A. Alshehri; D. W. Challener; R. R. Razonable
|